Literature DB >> 8221719

Characterization of inhibitory activities and binding mode of synthetic 6'-modified methyl N-acetyl-beta-lactosaminide toward rat liver CMP-D-Neu5Ac: D-galactoside-(2-->6)-alpha-D-sialyltransferase.

Y Kajihara1, H Kodama, T Wakabayashi, K Sato, H Hashimoto.   

Abstract

6'-Deoxy (12), 6'-thio (13), and 6'-O-tetrahydropyranosyl (14) analogues of methyl N-acetyl-beta-lactosaminide (3), were synthesized from lactose. NOE experiments proved that they adopt the same conformation as that of 3. Inhibition studies using these synthetic analogues, including the disulfide dimer 15, toward (2-->6)-alpha-sialytransferase (EC 2.4.99.1) revealed that the 6'-deoxy analogue 12 had remarkable inhibitory activity as the first acceptor-analogue inhibitor for this enzyme. It is noteworthy that the disulfide 15 also behaves as an inhibitor. The results indicated that chemical modification at the 6'-position of 3 did not cause much decrease in the binding affinity to the sialytransferase. Further, a novel possibility that the acceptor and the acceptor-analogue inhibitor can bind simultaneously to the sialytransferase was proposed based on the inhibition studies with 12 and CMP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221719     DOI: 10.1016/0008-6215(93)84251-z

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  3 in total

1.  New sialyltransferase inhibitors based on CMP-quinic acid: development of a new sialyltransferase assay.

Authors:  C Schaub; B Müller; R R Schmidt
Journal:  Glycoconj J       Date:  1998-04       Impact factor: 2.916

2.  Synthetic substrate analogues for UDP-GlcNAc: Man alpha 1-6R beta(1-2)-N-acetylglucosaminyltransferase II. Substrate specificity and inhibitors for the enzyme.

Authors:  F Reck; E Meinjohanns; M Springer; R Wilkens; J A Van Dorst; H Paulsen; G Möller; I Brockhausen; H Schachter
Journal:  Glycoconj J       Date:  1994-06       Impact factor: 2.916

Review 3.  Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?

Authors:  Silvia Pietrobono; Barbara Stecca
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.